Cancer biologics market is anticipated to grow significantly at a CAGR of 5.3% over the forecast period (2022-2028). The rising prevalence of various types of cancer such as prostate, brain, lung, pancreatic, and others is the prominent factor the demand for cancer biologics is increasing which in turn driving the market growth. According to the American Cancer Society, 1 man in 41 will die of prostate cancer, and around 268490 new cases and 34,500 deaths have been reported in 2022, in the US from prostate cancer. Similarly, the American Cancer Society’s estimated around 62,210 people which includes(32,970 men and 29,240 women), will be diagnosed with pancreatic cancer. Around 49,830 people including 25,970 men and 23,860 women die due to pancreatic cancer in 2022, and pancreatic cancer accounts for about 3% of all major cancers and 7% of deaths in the US.
To Request a Sample of our Report on Cancer Biologics Market: https://www.omrglobal.com/request-sample/cancer-biologics-market
Moreover, in 2022, an estimated 700,000 people in the US are living with a primary brain tumor, and around 88,970 and more will be diagnosed in 2022. The brain tumor significantly impacts the quality of life, as it is treated to be the deadly one. The 8,970 people included 63,040 people who suffered from non-malignant brain tumors, and 25,930 suffered from malignant as per the National Brain Tumor Society. The people across the world needs cancer biologics treatment, which includes various tests, vaccines, and antitoxins, that used as diagnostic, preventive, or therapeutics agents, to treat cancers. This is expected to surge the adoption of cancer biologics in cancer treatments with positive impact on the market gorwth.
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- by type, by distribution channel
- Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
Competitive Landscape- Abbvie Inc., Amgen USA Inc., Bristol Myers Squibb Co., F.Hoffmann-La Roche Ltd., Glaxo Smith Kelvin., Atra Zeneca, Cue Biopharma., Eli Lilly and Co., Genmab A/S, Boehringer Ingelheim Pharmaceutical Inc., and others.
Cancer Biologics Market– Segmentation
By Type
- Monoclonal Antibodies
- Cell and Gene Therapy
- Vaccines
By Distribution Channel
- Hospitals
- Clinics
A full Report of Cancer Biologics Market is Available @ https://www.omrglobal.com/industry-reports/cancer-biologics-market
Cancer Biologics Market – Segmentation by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- Astra Zeneca PLC
- Bayer AG
- Bioatla, Inc.
- Boehringer Ingelheim Pharmaceuticals Inc.
- Cue Biopharma
- Eli Lilly and Co.
- Engeneic Ltd.
- Genmab A/S
- Gilead Sciences Inc.
- Johnson & Johnson Services, Inc
- Merck & Co. Inc.
- Novartis Pharma AG
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Pyxis Oncology
- Sanofi S.A.
- Seagen Inc.
- Sensei Biotherapeutics, Inc.
- Takeda Pharmaceuticals Co. Ltd.
- Turnstone Biologics Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
